Breaking News, Collaborations & Alliances

BMS, Simcere To Co-develop Orencia SC in China

Will share commercialization, profits and losses

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb and Simcere Pharmaceutical Group have expanded their strategic partnership to collaborate on the development and commercialization of the subcutaneous (SC) formulation of BMS’s rheumatoid arthritis drug Orencia in China. Orencia SC is currently marketed in the U.S., Europe and Japan.   Simcere will perform and fund all development and regulatory activities to obtain market approval, based on a pre-agreed development plan. The companies will share commercialization resp...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters